Genetics and epigenetics of Alzheimer's disease

Postgraduate Medical Journal

Volumn 88, Issue 1043, 2012, Pages 522-529

  Alagiakrishnan, Kannayiram ^a   Gill, Sudeep S ^b   Fagarasanu, Andrei ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CD33 ANTIGEN; CYTOCHROME P450 2D6; EPHRIN RECEPTOR A1; ESTROGEN RECEPTOR; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PRESENILIN 1; PRESENILIN 2;

ALLELE; ALZHEIMER DISEASE; CHROMOSOME 1; CHROMOSOME 14; CHROMOSOME 21; DISEASE PREDISPOSITION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; HISTONE MODIFICATION; HUMAN; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PHARMACOGENETICS; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84865401658     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-130363     Document Type: Review

References (91)

1. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collobarative study of population-based cohorts. Neurological Diseases in the Elderly Research Group. Neurology 2000;54(11Suppl 5):S4e9.
2. Alzheimer's disease International Consortium. AD International World Alzheimer Report 2009. Alzheimer's disease International. London. http://www.alz.co.uk/. (accessed 24 Jan 2012).
3. Finch CE, Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer's disease: a position paper. Curr Alzheimer Res 2007;4:185e9.
4. Ding Q, Dinayuga E, Keller JN. Oxidative damage, protein synthesis and protein degradation in Alzheimer's disease. Curr Alzheimer Res 2007;4:73e9.
5. Alagiakrishnan K. Treating vascular risk factors and preventing Alzheimer's. Res Pract Alzheimers Dis 2007;12:59e65.
6. Jellinger KA, Mitter-Ferstl E. The impact of cerebrovascular lesion in Alzheimer's disease-a comparative autopsy study. J Neurol 2003;250:1050e5.
7. Querfurth HW, La Ferld FM. Alzheimer's disease. N Engl J Med 2010;362:329e44.
8. Alzenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509e17.
9. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56e67.
10. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702e16.
11. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 2008;258(Suppl 1):28e47.
12. Manolio TA. Genome wide association studies and assessment of the risk of disease. N Engl J Med 2010;363:166e76.
13. Mastroeni D, McKee A, Grover J, et al. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 2009;4:e6617.
14. Mastroeni D, Grover A, Delvaux E, et al. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging 2010;31:2025e37.
15. Pedersen NL. Reaching the limits of genome-wide significance in Alzheimer disease: back to the environment. JAMA 2010;303:1864e5.
16. Goate A, Chartier-Hartin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704e6.
17. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754e60.
18. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973e7.
19. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24e6.
20. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet 2006;36:405e15.
21. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007;39:17e23.
22. Ma SL, Lam LCW. Panel of genetic variations as a potential non-invasive biomarker for early diagnosis of Alzheimer's disease. Clinical Psychopharmacology and Neuroscience 2011;9:54e66.
23. Raber J, Huang Y, Ashford JW. Apo E genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641e50.
24. Jiang Q, Lee CY, Mandrekar S, et al. APOE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681e93.
25. Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010;5:e 13950.
26. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline; a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008;16:343e54.
27. Rubensztein DC. Apolipoprotein E: a review of its role in lipoprotein metabolism, neuronal growth and repair as a risk for Alzheimer's disease. Psychol Med 1995;25:223e9.
28. Seshadri S, Fitzpatrick AL, Ikram MA, et al; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303:1832e40.
29. Carrasquillo MM, Belbin O, Hunter TA, et al. Replications of CLU, CR1 and PICALM associations with alzheimer's disease. Arch Neurol 2010;67:961e4.
30. Jun G, Naj AC, Beecham GW, et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interaction with APOE genotypes. Arch Neurol 2010;67:1473e84.
31. Khera R, Das N. Complement Receptor 1: disease associations and therapeutic implications. Mol Immunol 2009;46:761e72.
32. Rogers J, Li R, Mastroenui D, et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 2006;27:1733e9.
33. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress A beta levels and deposition: evidence that ApoE regulates extracellular A beta metabolism in vivo. Neuron 2004;41:193e202.
34. Nuutinen T, Suuronen T, Kauppinen A, et al. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009;61:89e104.
35. Harol A, Wu F, Mattson MP, et al. Evidence for CALM in directing VAMP2 trafficking. Traffic 2008;9:417e29.
36. Carraquillo MM, Belbin O, Hunter TA, et al. Replication of EPHA1 and CD33 association with late-onset Alzheimer's disease: a multi-centre case-control study. Mol Neurodegener 2011;6:1e9.
37. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007;54:713e20.
38. Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 2010;15:756e66.
39. Morgan K. The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol 2011;37:353e7.
40. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768e78.
41. Reitz C, Cheng R, Rogaeva E, et al; Genetic and Environmental Risk in Alzheimer Disease 1 Consortium. Meta-analysis of the association between variants in SORL1 and Alzheimer's disease. Arch Neurol 2011;68:99e106.
42. Li Y, Grupe A, Rowland C, et al. DAPK 1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet 2006;15:2560e8.
43. Bertram L, Hittunen M, Parkinson M, et al. Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med 2005;352:884e94.
44. Sundar PD, Feingold E, Minster RL, et al. Gender-specific association of ATP binding cassette transporter 1(ABCA 1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol Aging 2007;28:856e62.
45. De Ferrari GV, Papassotiropoulos A, Biechele T, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A 2007;104:9434e9.
46. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168e77.
47. Pedersen NL. Reaching the limits of genome-wide significance in Alzheimer disease: back to the environment. JAMA 2010;303:1864e5.
48. Barabash A, Marcos A, Ancin I, et al. APOE, ACT and CHRNA 7 genes in the conversion from amnestic mild cognive impairment to Alzheimer's disease. Neurobiol Aging 2009;30:1254e64.
49. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996;47:387e400.
50. Tang G, Zhang M, Xie H, et al. Alpha 2 macroglobulin 11000 V polymorphism in Chinese sporadic Alzheimer's disease and Parkinson's disease. Neurosci Lett 2002;328:195e7.
51. Hatanaka Y, Kamino K, Fukuo K, et al. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population. Clin Genet 2000;58:319e23.
52. Li YJ, Scott WK, Zhang L, et al. Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer's and Parkinson's diseases. Neurobiol Aging 2006;27:1087e93.
53. Kolsch H, Jessen F, Wiltfang J, et al. Association of SORL 1 gene variants with Alzheimer's disease. Brain Res 2009;1264:1e6.
54. Belbin O, Carrasquillo MM, Crump M, et al. Investigation of 15 of the top candidate genes for late-onset Alzheimer's disease. Hum Genet 2011;129:273e82.
55. Martins CA, Oulhaj A, de Jager CA, et al. APOE alleles predict the rate of cognitive decline in Alzheimer's disease: a nonlinear model. Neurology 2005;65:1888e93.
56. Grimaldi LM, Casadei VM, Ferri C, et al. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 2000;47:361e5.
57. Licastro F, Veglia M, Chiappelli LM, et al. A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro pathological hall marks of Alzheimer's disease. Neurobiol Aging 2004;25:1017e22.
58. Blomqvist ME, Silburn PA, Buchanan DD, et al. Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics 2004;5:115e19.
59. Prince JA, Feuk L, Gu HF, et al. Genetic variation in a haplotype block spanning IDE influences Alzheimer's disease. Hum Mutat 2003;22:363e71.
60. Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 2001;71:777e9.
61. Roberts JS, Christensen KD, Green RC. Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics. Clin Genet 2011;80:407e14.
62. Tsankova N, Renthal W, Kumar A, et al. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8:355e67.
63. Graff J, Mansuy IM. Epigenetic codes in cognition and behaviour. Behav Brain Res 2008;192:70e87.
64. Nee LE, Lippa CF. Alzheimer's disease in 22 twin pairs-13-years follow-up: hormonal, infectious and traumatic factors. Demen Geriatr Cogn Disord 1999;10:148e51.
65. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005;102:10604e9.
66. Chouliaras L, Rutten BP, Kenis G, et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010;90:498e510.
67. Urdinquio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes and therapies. Lancet Neurol 2009;8:1056e72.
68. Silva PN, Gigek CO, Leal MF, et al. Promoter methylation analysis of SHRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer's disease. J Alzheimers Dis 2008;13:173e6.
69. Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr 2008;28:347e66.
70. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67:1328e31.
71. Chen KL, Wang SS, Yang YY, et al. The epigenetic effects of amyloid-beta (1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun 2009;378:57e61.
72. Belyaev ND, Nalivaeva NN, Makova NZ, et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer's disease. EMBO Rep 2009;10:94e100.
73. Guan JS, Haggarty SJ, Giacometti E, et al. HDAC 2 negatively regulates memory formation and synaptic plasticity. Nature 2009;459:55e60.
74. Whitelaw NC, Whitelaw E. Transgenerational epigenetic inheritance in health and disease. Curr Opin Genet Dev 2008;18:273e9.
75. Szyf M, McGowan P, Meaney MJ. The social environment and the epigenome. Environ Mol Mutagen 2008;49:46e60.
76. Helznep PE, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer's disease. Arch Neurol 2009;66:343e8.
77. Chandra V, Pandav R. Gene-environment interaction in Alzheimer's disease: a potential role for cholesterol. Neuroepidemiology 1998;17:225e32.
78. Mielke MM, Leoutsakos JM, Tschanz JT, et al. Interaction between vascular factors and the APOE 34 allele in predicting rate of progression in Alzheimer's disease. J Alzheimers Dis 2011;26:127e34.
79. Migliore L, Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 2009;667:82e97.
80. Fischer A, Sananbenesi F, Wang X, et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007;447:178e82.
81. Tang MX, Maestre G, Tsai WY, et al. Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Ann NY Acad Sci 1996;802:6e15.
82. T Cuenco KT, Lunetta K, Baldwin CT, et al. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol 2008;65:1640e8.
83. Wishart HA, Saykin AJ, Rabin LA, et al. Increased brain activation during working memory in cognitively intact adults with APOE epsilon 4 allele. Am J Psychiatry 2006;163:1603e10.
84. Kolsch H, Jessen F, Wiltfang J, et al. Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett 2008;440:68e71.
85. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opin Pharmacother 2005;6:1967e87.
86. Cacabelos R. Influence of pharmacogenetic factors on Alzheimer's disease therapeutics. Neurodegener Dis 2008;5:176e8.
87. Crentsil V. The pharmacogenomics of Alzheimer's disease. Ageing Res Rev 2004;3:153e69.
88. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Mini Rev Med Chem 2002;2:59e84.
89. Pola R, Flex A, Ciaburri M, et al. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett 2005;382:338e41.
90. O'Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003;13:231e9.
91. Shah RS, Lee HG, Xiongwei Z, et al. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008;62:199e207.